Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer
Miran Jang, Chan Kim, So Jung Kong, Hannah Yang, Won Suk Lee, Ho Yun Lee, Hong Jae Chon, Se-Hoon Lee · 2025
Read Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer by Miran Jang, Chan Kim, So Jung Kong, Hannah Yang, Won Suk Lee, Ho Yun Lee, Hong Jae Chon, Se-Hoon Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12714674.txt.
Description
Eight authors study in 2025 whether antibodies against the cancer drug atezolizumab change outcomes in advanced lung cancer. The drug can lose effect when the body makes antibodies that lower its level in blood. The team looked back at 86 patients treated at one Seoul center from 2018 to 2022.
Antibody levels rose sharply by week three, and about 37 percent of patients had strong levels. Those patients had shorter times with no growth and shorter survival, plus lower drug levels and fewer responses. High levels still marked poor outlook after other health factors were taken into account.
Catalog record
| CREATOR | Miran Jang, Chan Kim, So Jung Kong, Hannah Yang, Won Suk Lee, Ho Yun Lee, Hong Jae Chon, Se-Hoon Lee |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |